Palumbo Wealth Management LLC has made a significant investment by acquiring a stake in Boston Scientific Corporation, purchasing 25,330 shares valued at approximately $2.4 million. This acquisition took place during the third quarter of 2023, as indicated by the firm’s filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also adjusted their positions in Boston Scientific. For instance, First American Trust FSB increased its stake by 0.3%, now holding 80,908 shares worth about $7.9 million. Meanwhile, Mufg Securities Americas Inc. boosted its investment by 21.9%, acquiring an additional 7,168 shares to reach a total of 39,957 shares, valued at approximately $3.9 million. Other notable stakeholders include Baldwin Investment Management LLC, which grew its position by 5.4%, and Compound Planning Inc., which increased its holdings by 22.1%.
Institutional investors collectively own 89.07% of Boston Scientific’s stock, reflecting strong confidence in the company’s future.
Current Stock Performance and Trends
As of March 15, 2024, shares of Boston Scientific (NYSE: BSX) opened at $74.37. The company boasts a market capitalization of $110.36 billion and has a price-to-earnings ratio of 38.33. The stock has seen a 1-year low of $72.69 and a 1-year high of $109.50. Its fifty-day simple moving average stands at $88.87, while the 200-day average is at $96.32.
Boston Scientific’s financial health is further illustrated by a current ratio of 1.62 and a quick ratio of 1.08, along with a debt-to-equity ratio of 0.46.
Insider Activity and Analyst Ratings
In recent insider activity, Arthur C. Butcher, Executive Vice President, sold 17,313 shares on December 1, 2023, at an average price of $101.55, totaling approximately $1.76 million. Following this transaction, Butcher holds 23,600 shares valued at around $2.4 million. This sale represents a decrease of 42.32% in his position.
Similarly, Michael F. Mahoney, the company’s Chief Executive Officer, sold 160,901 shares on February 2, 2024, for about $15.04 million. Post-sale, Mahoney’s remaining shares are valued at approximately $132 million, indicating a 10.23% decrease in his ownership.
Analysts have provided mixed reviews regarding Boston Scientific’s stock. Weiss Ratings downgraded the stock from a “buy” to a “hold” rating in February 2024. Other firms have made adjustments to their price targets: Evercore lowered its target from $112.00 to $96.00, while Oppenheimer reduced its target from $125.00 to $100.00. Currently, one analyst rates the stock as a Strong Buy, twenty as Buy, and three as Hold, resulting in a consensus rating of “Moderate Buy” and an average price target of $108.36.
Boston Scientific Corporation, founded in 1979 and headquartered in Marlborough, Massachusetts, is a leading global medical device company. It specializes in developing, manufacturing, and marketing a diverse range of products designed for less-invasive medical procedures. The company’s portfolio addresses various medical conditions, including cardiovascular, digestive, urologic, pulmonary, and chronic pain issues.
For those interested in the latest updates on Boston Scientific and its stock performance, further insights can be found on financial news platforms and investment tracking websites.
